ISSN 3080-7670(Print)
ISSN 3080-7689(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3080-7670(Print)
ISSN 3080-7689(Online)

CODEN:ZYYYBQ
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社
(CAS)
DOI前缀:
https://doi.org/10.66106/zyyybq
国图集团 CIBTC
进口备案刊号:G015Z111

索引 检索 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。
DOI
ICI 哥白尼索引(波兰)
EuroPub 欧洲学术出版中心数据库(英国)
Academia 学术界(美国)
CJWK 长江文库(中国)
OALib 开放存取资源图书馆(美国)
Baidu Scholar 百度学术(中国)
Baidu Baike 百度百科(中国)
Google Scholar 谷歌学术(美国)
Microsoft Bing 微软学术(美国)
SPI-Hub 范德比尔特大学医学中心(美国)
ESJI 欧亚科学期刊索引(哈萨克斯坦)
ResearchBib 研究者索引(日本)
KIND CONGRESS(阿塞拜疆)
Sci Online 科学在线(中国澳门)
ASCI 亚洲科学引文索引(美国)
SCRIBD 数字图书馆(美国)
Yahoo! Search(美国)
Naver 搜遍(韩国)
SJIF 科学期刊索引(印度)
RJIF 研究期刊影响因子
Journament 质量评估与索引
Root Indexing 根索引(印度)
LivRe 巴西国家核能委员会CIN(巴西)
RCCSE 中国学术期刊收录(武汉大学)
Semantic Scholar 语义学者(美国)
CiteFactor 指标与信任索引(印度)
OAJ 全球OA期刊索引(中国)
Portico 数字保存库(美国)
Scite(美国)
EBSCO(美国)
MDPI scilit(瑞士)
Crossref 交叉引用(美国)
ProQuest 科睿唯安(美国)
ResearchGate 研究之门(德国)
COAJ 开放获取期刊数据(中国)
DOAJ 开放获取期刊目录(瑞典)
J-Gate 开放获取期刊门户(印度)
WorldCat 全球联机编目数据库(美国)
J-STAGE 学术信息电子期刊库(日本)
arXiv 学术论文预印本平台(美国)
PubMed 医学检索库(美国)
PubMed Central 医学全文库(美国)
The Lens 透镜学术(澳大利亚)
Scopus 爱思唯尔·斯高帕斯(荷兰)
ChatGPT OpenAI在线服务(美国)
EZB 电子期刊图书馆(德国)

Editing and Publishing
Quest Press Limited
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://zyyyj.scionline2025.com

  往期阅览 · All Issues-> 2025年 · 2025  
中医药研究与应用2025年第1卷第1期第5-8页,pISSN 3080-7670、eISSN 3080-7689 发布者:Quest Press 发布日期:2025/10/9
Open Access 下载2 浏览323

 

海马多鞭丸治疗脾肾阳虚型多囊卵巢综合征的临床疗效观察报告


雷天翔,雷启峰,雷启发

山东省临沂市兰陵县男女不孕不育研究所,山东临沂,277700

摘要:目的 探讨脾肾阳虚型多囊卵巢综合征(PCOS)予以海马多鞭丸的临床疗效。方法 研究对象均选自山东省临沂市兰陵县男女不孕不育研究所,随机数字表法抽取200 例多囊卵巢综合征(脾肾阳虚型)患者临床资料,入选时间均在2023.5~2024.5 期间,分组以右归丸合归脾汤加减治疗的100 例,命名对照组,采用海马多鞭丸治疗的100 例,命名实验组。组间对比临床疗效。结果 组间总有效率比较,实验组、对照组各为75.00%(75/100)vs 51.00%(51/100),实验组高于对照组(p<0.05);治疗前,两组在性激素各项指标对比不存在统计学意义(p>0.05),治疗后实验组的各项指标经评定改善效果更明显,组间相比差异显著(p<0.05)。结论 海马多鞭丸在治疗脾肾阳虚型多囊卵巢综合征疗效显著,有效改善卵巢功能,调节内分泌系统和机体代谢的功能,在临床有推广前景。

关健词:海马多鞭丸;脾肾阳虚;多囊卵巢综合征;疗效;性激素
Clinical Efficacy Observation Report of Haima Duobian Pills for Polycystic Ovary Syndrome with Spleen-Kidney Yang Deficiency

Tianxiang Lei,Qifeng Lei,Qifa Lei

Infertility Research Institute of Lanling County, Linyi, Shandong 277700, China

Abstract:Objective To explore the clinical efficacy of Haima Duobian Pills in polycystic ovary syndrome (PCOS) with deficiency of Yang in the spleen and kidney. Methods The research subjects were all selected from the Male and Female Infertility Research Institute of Lanling County, Linyi City, Shandong Province. Clinical data of 200 patients with polycystic ovary syndrome(spleen and Kidney Yang deficiency type) were randomly selected by the random number table method. The inclusion time was from May 2022 to May 2022. 100 cases were grouped and treated with modified Yoului Pills and Guipi Decoction, and the control group was named. One hundred cases treated with Haima Duobian Pills were named the experimental group. The clinical efficacy was compared between groups. Results The comparison of the total effective rate between groups showed that the experimental group and the control group were 75.00% (75/100) vs 51.00% (51/100), and the experimental group was higher than the control group (p<0.05). Before treatment, there was no statistical significance in the comparison of various sex hormone indicators between the two groups (p>0.05). After treatment, the improvement effect of various indicators in the experimental group was evaluated to be more obvious, and the difference between the groups was significant (p<0.05). Conclusion Haima Duobian Pills have a remarkable therapeutic effect on polycystic ovary syndrome of spleen and kidney Yang deficiency type. They can effectively improve ovarian function, regulate the endocrine system and the body's metabolic function, and have a promising promotion prospect in clinical practice.


Keywords : Haima Duobian Pills; Spleen-Kidney Yang Deficiency; Polycystic Ovary Syndrome (PCOS); Efficacy; Sex Hormones
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Quest Press Ltd.
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The QUEST PRESS publishes articles under the following open access license.
Quest Press
is a member of the following organizations.